Clinical Trials and Research
Jan 24, 2024
The transthyretin amyloidosis market size is projected to grow significantly during the forecast period (2023–2032) owing to the currently approved drugs, along…
Aug 27, 2023
The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy…
Apr 24, 2023
CARLSBAD, Calif., April 24, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Incexternal link, opens in a new tab. (Nasdaq: IONSexternal link, opens in a new tab) today…
Aug 03, 2022
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an…
Jul 12, 2021
Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year.The deal will see Novo pay $100…
Calquence six-year follow-up data reinforce long-term benefit in chronic lymphocytic
leukaemia, and data across multiple haematology assets showcase breadth of…
Published: Oct 09, 2023
- FDA Cites Insufficient Evidence of Clinical Meaningfulness -
- No Clinical Safety, Study Conduct, Drug Quality or Manufacturing…
- Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR…
Nexcella, Inc., a biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced…
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022